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Whole-genome array-based methylation analysis was performed on two cohorts of kidney allograft biopsies: 95 ob-
tained at implantation (82 brain-dead donors and 13 living donors), using EPIC BeadChips and 67 obtained after 
reperfusion (58 brain-dead donors and 9 living donors), using Infinium 450K Beadchips. Donor age ranged from 16 to 
73 years, and from 16 to 79 years, respectively. Comb-p was used to identify differentially methylated regions (DMRs). 
The genes mapped to DMRs with a FDR q-value <.0001 were selected for inguinity pathway analysis. 
Donor age associated significantly with methylation levels at 89,293 cpgs (10% of all probes) in the implantation 
cohort and 87,393 (20% postreperfusion (q-value < 0.05), adjusted gender cold ischemia time. q-value <0.0001 
corresponded to 17,077, respectively 15,225 differentially methylated regions. both cohorts, top enriched was wnt 
signalling pathway, which is involved kidney injury, repair fibrosis, as well renal senescence. 
There a strikingly pervasive association between DNA changes kidney. These occur preferentially genes suggesting 
link advanced chronic allograft dysfunction. 
InTRAVEnOUS ADMInISTRATIOn OF MESEnChYMAl STROMAl CEllS MODUlATES REnAl lIPID METAB-
OlISM In RATS.
Erpicum P, Rowart P, Poma L, Krzesinski J-M, Detry O, Jouret F. 
Liège, Belgium
Mesenchymal stromal cells (MSC) have been shown to attenuate renal ischemia/reperfusion (I/R) injury in rodents. 
Still, the mechanisms of such a nephroprotection remain unclear. Here, rats were intravenously infused with MSC 
(1.5x10^6 cells in 1 ml saline; MSCD-7 group, n=6) or equivalent volume of saline (SD-7 group, n=6) 7 days before 
kidney sampling. High-throughput RNA sequencing technology was used to compare transcriptomic renal profiles, 
using TopHat and Cufflinks open-source software tools. A total of 494 and 256 genes were found to be significantly 
(q-value <.05) down- and up-regulated in mscd-7 versus sd-7 groups, respectively. Hierarchical cluster analysis by 
“david” “webgestalt” softwares highlighted that the metabolic pathways mostly affected msc included adipogenesis, 
insulin signalling, fatty acid (fa) biosynthesis, il-6 b-cell receptor il-3 pathway nuclear receptors involved lipid me-
tabolism. Real-time qpcr immunoblotting analyses confirmed pivotal enzymes of fa biosynthesis were significantly 
downregulated group, whereas expression ppar alpha, a transcription factor oxidation, was induced msc. Additional-
ly, fat />CD36 – a key regulator of membrane uptake of FA – was increased in MSCD-7 kidneys, with a preferential 
localization in proximal tubules (PT). As a whole, our data suggest that MSC infusion causes critical modifications 
of lipid metabolism, including (i) down-regulation of FA biosynthesis; (ii) activation of PPAR alpha pathway, and (iii) 
prioritization of FA as sources of energy in PT cells, which may eventually prevent lipid peroxidation and attenuate 
renal I/R damage.
A GlYCOMIC SERUM MARKER AnAlYSED OnE WEEK AFTER lIVER TRAnSPlAnTATIOn IS An 
InDEPEnDEnT PREDICTOR OF GRAFT lOSS DURInG ThE FIRST YEAR AFTER lIVER TRAnSPlAnTATIOn. 
Verhelst X, Geerts A, Rogiers X, Vanlander A, Berrevoet F, Callewaert N, Troisi R, Van Vlierberghe H. 
Gent, Belgium
Poor graft function after liver transplantation (LT) remains a challenge for transplant professionals and sometimes 
requires retransplantation. Pretransplant estimation of graft function using scores like donor risk index has limited use 
in individual patients. Graft loss is increased in patients showing early allograft dysfunction after liver transplantation. 
However, biomarkers that reliably identify patients at risk for graft failure after LT are lacking. Analysis of N-glycans 
in serum (glycomics) has shown to reflect the underlying liver function in liver disease but has never been assessed 
after liver transplantation. The aim of this study was to assess the potential of serum glycomics as predictive markers 
for graft and patient survival after liver transplantation. 
In this monocentric prospective cohort 127 liver transplant patients were included between 1 December 2012 and 
31 December 2014. Serum samples were collected just before and on daily bases during the first 2 weeks after liver 
transplantation. Glycomic profiles were analysed using an optimized glycomic technology on a DNA sequencer. The 
major outcome parameters (graft and patient survival during 1 year) were related to the observed glycomic alterations 
and the best predictive association was searched for using cox regression analysis. 
The assessment of 2 serum glycans NG1A2F (an agalacto, core-alpha-1,6-fucosylated biantennary glycan structure) 
and NA3 (a triantennary glycan), combined as log(NG1A2F/NA3) on day 7 after liver transplantation was strongly 
associated with graft loss (hazard ratio = 7.222; p<0.001; 95% CI 2.352-22.182) and patient death (hazard ratio = 
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